A detailed history of State Street Corp transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 1,361,455 shares of OVID stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,361,455
Previous 1,354,371 0.52%
Holding current value
$1.44 Million
Previous $1.04 Million 54.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.75 - $1.3 $5,313 - $9,209
7,084 Added 0.52%
1,361,455 $1.61 Million
Q2 2024

Aug 14, 2024

BUY
$0.7 - $3.34 $139,106 - $663,738
198,724 Added 17.2%
1,354,371 $1.04 Million
Q1 2024

May 15, 2024

BUY
$2.72 - $4.04 $96,016 - $142,612
35,300 Added 3.15%
1,155,647 $3.52 Million
Q4 2023

Feb 14, 2024

BUY
$2.98 - $3.78 $33,638 - $42,668
11,288 Added 1.02%
1,120,347 $3.61 Million
Q3 2023

Nov 14, 2023

BUY
$3.23 - $3.97 $266,242 - $327,239
82,428 Added 8.03%
1,109,059 $4.26 Million
Q2 2023

Aug 14, 2023

BUY
$2.53 - $3.89 $2.11 Million - $3.25 Million
834,898 Added 435.45%
1,026,631 $3.37 Million
Q1 2022

May 16, 2022

BUY
$2.65 - $3.49 $124,242 - $163,625
46,884 Added 32.37%
191,733 $602,000
Q3 2021

Nov 15, 2021

SELL
$3.31 - $4.04 $39,720 - $48,480
-12,000 Reduced 7.65%
144,849 $487,000
Q2 2021

Aug 16, 2021

SELL
$3.3 - $4.49 $3.46 Million - $4.7 Million
-1,047,516 Reduced 86.98%
156,849 $613,000
Q1 2021

May 17, 2021

BUY
$2.42 - $4.47 $1.13 Million - $2.08 Million
464,925 Added 62.88%
1,204,365 $4.84 Million
Q4 2020

Feb 16, 2021

BUY
$2.28 - $6.84 $27,834 - $83,502
12,208 Added 1.68%
739,440 $1.71 Million
Q3 2020

Nov 10, 2020

SELL
$5.39 - $8.24 $47,022 - $71,885
-8,724 Reduced 1.19%
727,232 $4.17 Million
Q2 2020

Aug 14, 2020

BUY
$2.67 - $7.91 $1.97 Million - $5.82 Million
735,956 New
735,956 $5.42 Million

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $74.6M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.